Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: Current overall survival after primary tumor resection

Cancer

Volumn 117, Issue 21, 2011, Pages 4916-4924

  Rutkowski, Piotr ^a   Wozniak, Agnieszka ^b   Dȩbiec Rychter, Maria ^b   Kåkol, Michał ^c   Dziewirski, Wirginiusz ^a   Zdzienicki, Marcin ^a   Ptaszynski, Konrad ^a   Jurkowska, Monika ^a   Limon, Janusz ^c   Siedlecki, Janusz A ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

gastrointestinal stromal tumor; genotype; prognosis; stage; surgery

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXON; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; GENE MUTATION; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MITOSIS INDEX; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE C KIT; PDGFRA GENE; POINT MUTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 80054828280     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26079     Document Type: Article

References (39)

1. Joensuu H,. Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006; 17: 280-286.
2. Miettinen M, Lasota J,. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001; 438: 1-12. (Pubitemid 32128184)
3. Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA,. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Recent Pat Anticancer Drug Discov. 2008; 3: 88-99.
4. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279: 577-580. (Pubitemid 28067289)
5. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors 1 centimeter or less in size. Am J Pathol. 2002; 160: 1567-1572. (Pubitemid 34525636)
6. Corless CL, Fletcher JA, Heinrich MC,. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004; 22: 3813-3825. (Pubitemid 41095223)
7. Lasota J, Miettinen M,. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol. 2006; 23: 91-102. (Pubitemid 44692417)
8. Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007; 31: 113-120. (Pubitemid 46036910)
9. Wozniak A, Floris G, Debiec-Rychter M, Sciot R, Schoffski P,. Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies. Cancer Invest. 2010; 28: 839-848.
10. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF,. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231: 51-58. (Pubitemid 30043939)
11. DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008; 112: 608-615. (Pubitemid 351186201)
12. DeMatteo RP, Heinrich MC, El-Rifai WM., Demetri G,. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002; 33: 466-477. (Pubitemid 34747865)
13. Roberts PJ, Eisenberg B,. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002; 38 (suppl 5): S37-S38.
14. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ,. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001; 136: 383-389. (Pubitemid 32322809)
15. Aparicio T, Boigea V, Sabourin JC, Crenn P, Ducreux M, Le Cesne A, Bonvalot S,. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol. 2004; 30: 1098-1103. (Pubitemid 40267815)
16. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-480. (Pubitemid 34879334)
17. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368: 1329-1338. (Pubitemid 44528723)
18. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364: 1127-1134. (Pubitemid 39296599)
19. DeMatteo R, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373: 1079-1104.
20. Fletcher C, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002; 33: 459-465. (Pubitemid 34747864)
21. Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007; 14: 2018-2027. (Pubitemid 46988258)
22. Joensuu H,. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39: 1411-1419.
23. Miettinen M, Lasota J,. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23: 70-83. (Pubitemid 44692418)
24. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw. 2007l; 5 (suppl 2): S1-S29.
25. Miettinen M, Sobin LH, Lasota J,. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005; 29: 52-68. (Pubitemid 40023952)
26. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006; 30: 477-489. (Pubitemid 43740149)
27. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Staging Manual. 7th ed. New York: Springer; 2009.
28. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Handbook. 7th ed. New York: Springer; 2010.
29. Ruka W, Rutkowski P, Kulig J, et al. Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2008 [article in Polish]. Nowotwory. 2008; 58: 537-549.
30. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004; 40: 689-695. (Pubitemid 38326618)
31. Hassan I, You N, Shyyan R, et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. 2007; 15: 52-59.
32. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res. 2003; 9: 3329-3337. (Pubitemid 37082727)
33. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M,. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest. 2004; 84: 874-883. (Pubitemid 38833247)
34. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol. 2005; 23: 6190-6198.
35. Gold JS, van der Zwan SM, Gonen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol. 2007; 14: 134-142. (Pubitemid 44954280)
36. Ng E, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Ann Surg. 1992; 215: 68-77.
37. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001; 8: 50-59. (Pubitemid 32140424)
38. Perez EA, Gutierrez JC, Jin X, et al. Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg. 2007; 11: 114-125.
39. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26: 620-625. (Pubitemid 351264357)